MiMedx Group (NASDAQ:MDXG) Price Target Cut to $12.00 by Analysts at Craig Hallum

MiMedx Group (NASDAQ:MDXG) had its price objective trimmed by Craig Hallum from $14.00 to $12.00 in a research report report published on Thursday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

Other equities research analysts have also recently issued research reports about the company. StockNews.com raised MiMedx Group from a buy rating to a strong-buy rating in a research note on Thursday, July 11th. HC Wainwright reissued a buy rating and issued a $11.00 price target on shares of MiMedx Group in a research note on Wednesday, May 1st. Finally, Cantor Fitzgerald reissued an overweight rating and issued a $11.00 price target on shares of MiMedx Group in a research note on Thursday. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of Buy and an average target price of $12.00.

MiMedx Group Trading Down 3.3 %

Shares of MDXG stock opened at $6.46 on Thursday. The stock has a market cap of $953.52 million, a price-to-earnings ratio of 14.68 and a beta of 1.98. The stock has a 50-day moving average of $7.09 and a 200-day moving average of $7.43. The company has a current ratio of 3.85, a quick ratio of 2.71 and a debt-to-equity ratio of 0.11. MiMedx Group has a 1-year low of $5.57 and a 1-year high of $9.27.

Institutional Investors Weigh In On MiMedx Group

Several large investors have recently added to or reduced their stakes in MDXG. AJOVista LLC acquired a new stake in MiMedx Group during the fourth quarter worth approximately $25,000. Headlands Technologies LLC acquired a new stake in MiMedx Group during the first quarter worth approximately $27,000. Entropy Technologies LP acquired a new stake in MiMedx Group during the first quarter worth approximately $99,000. Loudon Investment Management LLC acquired a new stake in MiMedx Group during the fourth quarter worth approximately $105,000. Finally, Shell Asset Management Co. bought a new position in MiMedx Group in the first quarter worth approximately $113,000. Institutional investors and hedge funds own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.